Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.
about
Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosisNon-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosisEvaluation and Management of Hepatic Encephalopathy: Current Status and Future DirectionsManagement of overt hepatic encephalopathySafety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathyHepatic Encephalopathy: From the Pathogenesis to the New Treatments.Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options.Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascitesEfficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial.The Evolution of Transjugular Intrahepatic Portosystemic Shunt: Tips.Rifaximin in the treatment of hepatic encephalopathy.Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.Emerging drugs for hepatic encephalopathy.Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review.Rifaximin: recent advances in gastroenterology and hepatologyDisaccharides in the treatment of hepatic encephalopathy.Update on management of patients with overt hepatic encephalopathy.Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes.Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis.Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with recurrent variceal hemorrhage.Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt.Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease ≥15.The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension: current status.Rifaximin therapy and hepatic encephalopathy: Pros and cons.Transjugular intrahepatic portosystemic shunt in the management of refractory ascitesHepatic encephalopathy therapy: An overview.Rifaximin as treatment for hepatic encephalopathy: some considerations.Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests.Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.Hepatic encephalopathyRace and Gradient Difference Are Associated with Increased Risk of Hepatic Encephalopathy Hospital Admission After Transjugular Intrahepatic Portosystemic Shunt PlacementManagement of hepatic encephalopathy
P2860
Q24185782-E6CC134A-C89C-4AB0-BE2A-C0048C33DDE5Q24185895-D5A0F810-D7D1-4FBA-9E82-F4B081199F37Q26744689-028D0A21-8F0A-4CFB-B32E-C72296BD4C2EQ26830789-E1F7B82E-A554-466F-8F50-547EB5DFDBB8Q28236913-2121367F-767F-4DD1-ABB4-DF163AF4B86BQ30381016-CA99F25F-25DB-43CB-98A3-8528F222F4C2Q33805285-D3A657CB-D76A-4981-A3F0-8CB53D7857A0Q35720298-9A0EED62-BA40-468E-9C67-0E6D348F2679Q36579559-6CD8B4AE-ABF1-45F5-9F9A-9D8780D4DC68Q36961977-F7D23A28-6930-4711-A066-9A47DD51663AQ37355818-98770608-305A-465C-8B19-3D19326445D9Q37489472-424A5005-37E8-4D72-A2FD-D919F244C5F4Q37529838-52DD8F75-FEAE-4635-9825-C5C1684B9CB2Q37830756-3067D71B-C89F-493E-A60F-DC6E4922C025Q38074951-6BE5310D-E946-445E-AB22-E54C21147111Q38086120-E282C182-DAD1-44B8-A833-237E4D3C66DCQ38129187-44E1D119-514D-4E47-9DC0-0B44E9B42A91Q38244333-DC0B5BAD-CF03-45EE-B359-274AC795A0DFQ38260345-BE22A1DA-F109-4AA8-9F45-F24E713C6750Q38809023-4B87CE22-5A48-482D-9D71-C098476EA237Q39826745-12DDA5E4-A860-4C44-A60B-8BCD8E55AF47Q39960434-55C1656A-2592-4248-8ABD-291FBC88C9DAQ40765449-73DE3EE3-67C7-4D70-9235-F569FAAF0C30Q41842278-32677E36-CB22-4E65-BF47-D3ECFE91422FQ42324150-ECAE94DB-8926-43D5-B13C-47EB4D2DAE22Q42593002-D5832829-B834-401F-B323-957BD4FD0A60Q42730495-9E9EC7A9-7AF9-4F7D-B093-471268912689Q43223549-7C27F0BF-796D-4E70-A269-C83C3130AF0BQ44333628-BF100548-345E-482E-BD20-53ABD8771CD2Q50643497-FFB30988-A9DF-481B-A99C-477990C3B29AQ52150971-FE866C18-D97C-4F1E-BF1F-49E38ECC4F26Q56456330-F6B494FF-5658-45D6-AC7B-2E7CFACE0BD0Q57300679-23B05B3A-AD09-4DF8-B196-BF911BC44E3AQ58687496-C979AA88-2393-455F-97D9-BB659EFA816D
P2860
Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Pharmacological prophylaxis of ...... a randomized controlled study.
@en
Pharmacological prophylaxis of ...... a randomized controlled study.
@nl
type
label
Pharmacological prophylaxis of ...... a randomized controlled study.
@en
Pharmacological prophylaxis of ...... a randomized controlled study.
@nl
prefLabel
Pharmacological prophylaxis of ...... a randomized controlled study.
@en
Pharmacological prophylaxis of ...... a randomized controlled study.
@nl
P2093
P50
P1476
Pharmacological prophylaxis of ...... a randomized controlled study.
@en
P2093
Filippo M Salvatori
S Angeloni
P304
P356
10.1016/J.JHEP.2004.12.028
P577
2005-05-01T00:00:00Z